Cargando…
Extended interval BNT162b2 vaccination enhances peak antibody generation
The BNT162b2 vaccine is highly effective against COVID-19 infection and was delivered with a 3-week time interval in registration studies(1). However, many countries extended this interval to accelerate population coverage with a single vaccine. It is not known how immune responses are influenced by...
Autores principales: | Parry, Helen, Bruton, Rachel, Stephens, Christine, Bentley, Christopher, Brown, Kevin, Amirthalingam, Gayatri, Hallis, Bassam, Otter, Ashley, Zuo, Jianmin, Moss, Paul |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8795435/ https://www.ncbi.nlm.nih.gov/pubmed/35087066 http://dx.doi.org/10.1038/s41541-022-00432-w |
Ejemplares similares
-
Differential immunogenicity of BNT162b2 or ChAdOx1 vaccines after extended-interval homologous dual vaccination in older people
por: Parry, Helen, et al.
Publicado: (2021) -
Immunogenicity of single vaccination with BNT162b2 or ChAdOx1 nCoV-19 at 5–6 weeks post vaccine in participants aged 80 years or older: an exploratory analysis
por: Parry, Helen, et al.
Publicado: (2021) -
mRNA vaccination in people over 80 years of age induces strong humoral immune responses against SARS-CoV-2 with cross neutralization of P.1 Brazilian variant
por: Parry, Helen, et al.
Publicado: (2021) -
Immunogenicity of standard and extended dosing intervals of BNT162b2 mRNA vaccine
por: Payne, Rebecca P., et al.
Publicado: (2021) -
Vaccine subtype and dose interval determine immunogenicity of primary series COVID-19 vaccines in older people
por: Parry, Helen, et al.
Publicado: (2022)